These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35959594)

  • 1. Five cases of seronegative persistent inflammatory monoarthritis improved with biological therapy.
    Izumiyama T; Mori Y; Hamada S; Kurishima H; Mori N; Aizawa T
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):307-314. PubMed ID: 35959594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of persistent inflammatory large joint monoarthritis.
    Byng-Maddick R; Jeyalingam L; Keat A
    Clin Rheumatol; 2012 Dec; 31(12):1657-62. PubMed ID: 23108886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Joint Distribution and Two-Year Outcome in 347 Patients With Monoarthritis of Less Than Sixteen Weeks' Duration.
    Norli ES; Brinkmann GH; Kvien TK; Bjørneboe O; Haugen AJ; Nygaard H; Thunem C; Lie E; Mjaavatten MD
    Arthritis Care Res (Hoboken); 2020 May; 72(5):705-710. PubMed ID: 28777897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juvenile Idiopathic Arthritis.
    Barut K; Adrovic A; Şahin S; Kasapçopur Ö
    Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
    Agarwal SK
    J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulphasalazine treatment in protracted familial Mediterranean fever arthritis.
    Bakkaloglu SA; Aksu T; Goker B; Unlusoy A; Peru H; Fidan K; Soylemezoglu O; Hasanoglu E; Buyan N
    Eur J Pediatr; 2009 Aug; 168(8):1017-9. PubMed ID: 19034507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical courses and predictors of outcomes in patients with monoarthritis: a retrospective study of 171 cases.
    Jeong H; Kim AY; Yoon HJ; Park EJ; Hwang J; Kim H; Ahn JK; Lee J; Koh EM; Cha HS
    Int J Rheum Dis; 2014 Jun; 17(5):502-10. PubMed ID: 24330384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
    Quinn MA; Green MJ; Marzo-Ortega H; Proudman S; Karim Z; Wakefield RJ; Conaghan PG; Emery P
    Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seronegative spondyloarthropathy in familial Mediterranean fever.
    Langevitz P; Livneh A; Zemer D; Shemer J; Pras M
    Semin Arthritis Rheum; 1997 Oct; 27(2):67-72. PubMed ID: 9355205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated tuberculous monoarthritis mimicking oligoarticular juvenile rheumatoid arthritis.
    Al-Matar MJ; Cabral DA; Petty RE
    J Rheumatol; 2001 Jan; 28(1):204-6. PubMed ID: 11196526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to treat refractory arthritis in lupus?
    Artifoni M; Puéchal X
    Joint Bone Spine; 2012 Jul; 79(4):347-50. PubMed ID: 22341583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of biologic therapies in the treatment of rheumatoid arthritis.
    Wang D; Li Y; Liu Y; Shi G
    Curr Pharm Biotechnol; 2014; 15(6):542-8. PubMed ID: 25213363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.